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Abstract
Background: Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate
cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-
specific-antigen (PSA) in men with germline BRCA1/2 mutations.
Objective: To report the utility of PSA screening, PrCa incidence, positive predictive
value of PSA, biopsy, and tumour characteristics after 3 yr of screening, by BRCA status.
Design, setting, and participants: Men aged40–69 yrwith a germline pathogenicBRCA1/
2 mutation and male controls testing negative for a familial BRCA1/2 mutation were
recruited. Participants underwent PSA screening for 3 yr, and if PSA>3.0 ng/ml, men
were offered prostate biopsy.
Outcomemeasurements and statistical analysis: PSA levels, PrCa incidence, and tumour
characteristics were evaluated. Statistical analyses included Poisson regression offset by
person-year follow-up, chi-square tests for proportion t tests for means, and Kruskal-
Wallis for medians.
Results and limitations: A total of 3027 patients (2932 unique individuals) were
recruited (919 BRCA1 carriers, 709 BRCA1 noncarriers, 902 BRCA2 carriers, and 497
BRCA2 noncarriers). After 3 yr of screening, 527 men had PSA>3.0ng/ml, 357 biopsies
were performed, and 112 PrCa cases were diagnosed (31 BRCA1 carriers, 19 BRCA1
noncarriers, 47 BRCA2 carriers, and 15 BRCA2 noncarriers). Higher compliance with
biopsy was observed in BRCA2 carriers compared with noncarriers (73% vs 60%). Cancer
incidence rate per 1000 person years was higher in BRCA2 carriers than in noncarriers
(19.4 vs 12.0; p = 0.03); BRCA2 carriers were diagnosed at a younger age (61 vs 64 yr; p =
0.04) and were more likely to have clinically signiﬁcant disease than BRCA2 noncarriers
(77% vs 40%; p = 0.01). No differences in age or tumour characteristics were detected
between BRCA1 carriers and BRCA1 noncarriers. The 4 kallikrein marker model discrim-
inated better (area under the curve [AUC] = 0.73) for clinically signiﬁcant cancer at
biopsy than PSA alone (AUC=0.65).
Conclusions: After 3 yr of screening, compared with noncarriers, BRCA2 mutation
carriers were associated with a higher incidence of PrCa, younger age of diagnosis,
and clinically signiﬁcant tumours. Therefore, systematic PSA screening is indicated for
menwith a BRCA2mutation. Further follow-up is required to assess the role of screening
in BRCA1 mutation carriers.
Patient summary: We demonstrate that after 3 yr of prostate-speciﬁc antigen (PSA)
testing, we detect more serious prostate cancers in men with BRCA2 mutations than in
those without these mutations. We recommend that male BRCA2 carriers are offered
systematic PSA screening.
© 2019 The Authors. Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://creati-
vecommons.org/licenses/by-nc-nd/4.0/).
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It is well established that BRCA2 gene mutations cause a
higher risk of prostate cancer (PrCa), with an estimated
relative risk of 2.5–8.6-fold by age 65yr [1,2], and are
associated with earlier-onset, clinically significant disease. A
number of retrospective studies report higher rates of lymph
node involvement, distant metastasis at diagnosis, and
higher mortality rates in mutation carriers [3–6]. Germline
BRCA2 mutation status is reported to be an independent
prognostic factor for poorer outcome [3]. Furthermore,
tumours of BRCA2 mutation carriers with localised PrCa
have been demonstrated to exhibit genomic instability more
typically seen in metastatic castration-resistant PrCa [7].
There is debate aboutwhether there is an increased risk of
PrCa for BRCA1mutation carriers, with an estimated relative
risk of 1.8–3.75-fold by age 65yr [8] and some evidence of
more clinically significant disease [3,9]; however, this
warrants further research. It is hypothesised that targeted
screening in BRCA1/2 carriers facilitates early detection.
The controversies of using prostate-specific antigen
(PSA) screening in the general population are welldocumented, but PSA remains the most effective PrCa
biomarker currently available [10–12]. Efforts to improve
sensitivity and specificity of PSA by incorporating other
biological markers, such as the 4 kallikrein (4K) marker
panel [13,14], PrCa risk calculators [15,16], magnetic
resonance imaging (MRI) [17,18], and genetic markers
[19,20], into screening algorithms are under evaluation.
The IMPACT study (Identification of Men with a genetic
predisposition to ProstAte Cancer: Targeted screening inmen
at higher genetic risk and controls; http://impact.icr.ac.uk/) is
an international, multicentre study evaluating targeted PrCa
screening in men with BRCA1/2 mutations. IMPACT aims to
evaluate the utility of PSA screening in detecting clinically
significant PrCa (definedas intermediate- orhigh-riskdisease
using the National Institute for Health and Care Excellence
[NICE] guidelines [21]), PrCa incidence, positive predictive
value (PPV) of biopsy using a PSA threshold of 3.0ng/ml, and
tumour characteristics in order to establish whether PSA
screening detects clinically significant disease in this
population compared with the noncarrier control group.
An analysis of the baseline screen for nearly 2500 men
enrolled in IMPACT supported the use of targeted PSA
E U RO P E AN URO L OGY 76 ( 2 019 ) 8 31 – 8 4 2834screening in BRCA1/2 mutation carriers, suggesting that
screening detects a high proportion of clinically significant
tumours [22]. Moreover, we have also demonstrated that
PSA is more predictive of PrCa in BRCA1/2 carriers than in
noncarriers [23]. It has been reported that men with
germline BRCA1/ BRCA2 mutations, on active surveillance
for low-risk PrCa, are at a higher risk of reclassification to
higher-grade PrCa than noncarriers [24].
National Comprehensive Cancer Network guidelines
advise PrCa screening to begin at 45 yr for male BRCA2
carriers, consider the same for BRCA1 carriers, and perform
routine BRCA1/2 testing for menwith high-risk PrCa, family
history, or metastatic disease [25,26].
The aims of this study were to evaluate the utility of PSA
screening, by assessing PrCa prevalence/incidence, PPV of
biopsy, and tumour characteristics. A secondary aim was to
evaluate the addition of 4K markers to the algorithm
predicting biopsy outcome (full details of this analysis can
be found in the Supplementary material).
2. Patients and methods
The IMPACT study design has been reported previously
[22,27,28] and is summarised in Fig. 1. The protocol was
approved by the West-Midlands Research and Ethics
Committee in the UK (reference: 05/MRE07/25) and
subsequently by each participating institution’s local
committee. All participants provided written consent, and
interim analyses are presented to the Independent Data and
Safety Monitoring Committee biannually.
The target sample is 500 BRCA1 and 350 BRCA2mutation
carriers, anda control groupof 850menwhohaveundergone
predictive testing and tested negative for a pathogenic
BRCA1/2 mutation known to be present in their family.
IMPACT has beenpowered to detect a two-fold PrCa risk over
5yr of screening, with 80% power at the p< 0.01 level.
Between October 2005 and February 2013,men aged 45–
69 yr in The Netherlands and 40–69 yr in all other countries
were recruited from families with knownpathogenic BRCA1
or BRCA2 mutations. Further detail of the inclusion criteria
were described previously [22,27,28]. Participants were
screened annually in all centres except for those in
The Netherlands, which screened biennially in accordance
with local regulations. Recruitment was extended to
December 2015, and a subset of 95 BRCA2 noncarriers
was sequenced for BRCA1/2 mutations and used as the
control group to cover the loss of numbers that resulted in
removing The Netherlands cohort from cumulative analyses
and include them as BRCA1 noncarriers.
All participants underwent annual PSA testing for four
screening rounds. If PSA was >3.0 ng/ml, transrectal
ultrasound–guided prostate biopsy (PB)was recommended.
Decision to biopsy was based on this single PSA level; PSA
was not repeated prior to biopsy unless clinically indicated.
Centres were requested to follow a standard biopsy
protocol, consisting of 10 and 12 biopsy cores taken from
specific locations within the prostate gland. Individuals
with a benign PB continued annual PSA follow-up. A repeat
PB was recommended if PSA was >50% of the pre-PB PSA[29] (Fig. 1). The local histopathologist at each centre
reported the biopsy results to guide treatment in accor-
dance with local guidelines. Cancers were defined using the
NICE criteria, and were deemed “clinically significant” if
classified as of intermediate or high risk according to these
guidelines [21]. Whenever high-grade prostate intraepithe-
lial neoplasia or atypical small acinar proliferation was
detected, the biopsy was repeated within 3–6 mo.
The IMPACT results have been compared with the
Göteborg cohort of the ERPSC study. This Swedish general
population cohort of men aged 50–64yr was offered
biennial PSA screening with further investigations for
PSA>3.0 ng/ml and therefore were the closest general
population group available for comparison.
2.1. Statistical analysis
Statistical analyses were undertaken using Stata 14.2 Stata-
Corp. 2015. Stata Statistical Software: Release 14. College
Station, TX: StataCorp LP and GraphPad QuickCalcs Web
site: https://www.graphpad.com/quickcalcs (accessed Au-
gust 2019).
PrCa prevalence for individuals with PSA>3.0 ng/ml at
the first PSA test was calculated. The cumulative incidence
was calculated at the fourth screening round, stratified by
age group, tumour-node-metastasis stage, and Gleason
score, and compared by mutation status using Poisson
regression offset by person-year follow-up, adjusted for age,
ethnicity, and country. Proportions of screen-detected
disease and PPV of PB were compared between groups
using the chi-square test. Fisher’s exact and Kruskal-Wallis
tests were used to compare median age, PSA, and tumour
characteristics between groups.
Analyses were performed on the whole cohort and by
BRCA status. Secondary analyses were conducted excluding
prevalent cancers (cancers diagnosed within <12 mo of
enrolment). A p value of <0.05 was considered statistically
significant.
3. Results
3.1. Study population
A total of 3027 persons (2932 unique individuals) were
recruited from 65 centres in 20 countries over 120 mo
(Supplementary Table 1): 919 BRCA1 carriers, 709 BRCA1
noncarriers, 902 BRCA2 carriers, and 497 BRCA2 noncarriers.
Ninety-five BRCA2 noncarriers sequenced for both BRCA1/2
mutations were included in both control cohorts. The
cohorts were overrecruited, as advised by the study’s
Independent Data Monitoring Committee. The rationale
was that overrecruitment would only strengthen the data
and would compensate for any participants who withdrew
from the study.
Themajority of participants were Caucasian (97%), highly
educated, and in work (Supplementary Table 2); median
enrolment age was 54yr; 24% of men reported urinary
symptoms and 36% previously had at least one PSA test; and
31% reported a family history of PrCa. No statistically
[(Fig._1)TD$FIG]
Fig. 1 – Study design algorithm.
ASAP=atypical small acinar proliferation; FU= follow-up; MRI =magnetic resonance imaging; PIN=prostate intraepithelial neoplasia; PrCa=prostate
cancer; PSA=prostate-specific-antigen; Re-BX= repeat biopsy.
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Table 1 – Prostate cancer detection rates after four rounds of screening.
Total cohorta Mutation status
BRCA2+ BRCA2– BRCA1+ BRCA1–
Baseline (“yr 1”)
Unique individuals, n (%) 2932 902 (30) 497(16) 919 (30) 709 (24)
Total PSAs taken, n 2931 902 497 919 708
Median PSA (IQR) 0.9 (0.6-1.5) 0.9 (0.5-1.5) 0.9 (0.6-1.4) 0.9 (0.5-1.4) 1.0 (0.6-1.7)
PSA>3ng/ml, n (%) 228 (7.5) 68 (7.5) 29 (5.8) 73 (7.9) 61 (8.6)
PSA>3ng/ml requiring action, n 228 68 29 73 61
Biopsies, n (biopsy rate %) 180 (79) 56 (82) 19 (66) 57 (78) 49 (75)
Including repeats, n 195 61 21 62 52
Benign, n 107 29 12 32 35
ASAP/HG PIN, n 13 5 0 6 2
Malignant (PrCa incidence), n (%, 95 CI) 69 (2.4, 1.8-3.0) 25 (2.8, 1.7-3.8) 7 (1.4, 3.7-2.4) 24 (2.6, 1.6-3.6) 13 (1.8, 0.8-2.8)
Diff. in detection rate: BRCA+ vs BRCA– (%, 95 CI) (1.4, -0.1-2.9) (0.8, -0.6-2.2)
p value for detection rate: BRCA+ vs BRCA– 0.10 0.3
Diagnosed within 6 mo of entry, n 65 25 6 22 12
Diagnosed within 12 mo of entry, n 68 25 7 23 13
PPV of biopsy (%, 95 CI) (35, 29-43) (41, 29-53) (33, 13-53) (39, 27-51) (25, 13-37)
Diff. in PPV, biopsy: BRCA+vs BRCA– (%, 95 CI) (8, 16-31) (14, 3-31)
p value for PPV, biopsy: BRCA+ vs BRCA– 0.5 0.12
PPV of PSA>3ng/ml requiring action (%, 95 CI) (30, 24-37) (37, 25-48) (24, 9-40) (33, 22-44) (21, 11-32)
Diff. in PPV, PSA>3: BRCA+vs BRCA– (%, 95 CI) (13, 7-32) (12, 3-26)
p value for PPV, PSA>3: BRCA+vs BRCA– 0.2 0.14
3-yr follow-up (“yr 4”)
Total PSAs taken, n (%) 9363 3108 (32) 1600 (16) 2847 (29) 2183 (22)
Median PSA (IQR) 0.9 (0.6-1.5) 0.9 (0.6-1.5) 0.9 (0.6-1.5) 0.9 (0.5-1.5) 1.0 (0.6-1.7)
PSA>3ng/ml, n (%) 695 (7.4) 200 (6.4) 117 (7.3) 218 (7.7) 182 (8.3)
PSA>3ng/ml requiring action, n (%) 527 (5.6) 150 (4.8) 84 (5.3) 138 (4.8) 126 (5.8)
Biopsies, n (biopsy rate%) 332 (63) 110 (73) 50 (60) 93 (67) 89 (71)
Including repeats, n 357 122 54 98 95
Benign, n 208 59 32 60 67
ASAP/HG PIN, n 26 10 5 7 6
Malignant (PrCa incidence), n (%, 95 CI) 112 (3.8, 3.2-4.6) 47 (5.2, 3.8-6.7) 15 (3.0, 1.5-4.5) 31 (3.4, 2.2-4.5) 19 (2.7, 1.5-3.9)
Diff. in detection rate: BRCA+ vs BRCA– (%, 95 CI) (2.2, 0.1-4.2) (0.7, 0.9-2.3)
p value for detection rate: BRCA+ vs BRCA– 0.057 0.4
PPV of biopsy (%, 95 CI) (31, 27-36) (39, 30-47) (28, 16-40) (32, 22-41) (20, 12-28)
Diff. in PPV, biopsy: BRCA+vs BRCA– (%, 95 CI) (11, 4-25) (12, 0.6-24)
p value for PPV, biopsy: BRCA+ vs BRCA– 0.17 0.065
PPV of PSA>3ng/ml requiring action (%, 95 CI) (21, 18-25) (31, 24-39) (18, 10-26) (23, 16-29) (15, 9-21)
Diff. in PPV, PSA>3: BRCA+vs BRCA– (%, 95 CI) (13, 2-25) (7, 2-17)
p value for PPV, PSA>3: BRCA+vs BRCA– 0.025 0.13
Prevalence of PrCa in all PSAs (%, 95 CI) (1.2, 1-1.4) (1.5, 1.1-1.9) (0.9, 0.5-1.4) (1.1, 0.7-1.5) (0.9, 0.5-1.2)
Diff. in prevalence of PrCa: BRCA+ vs BRCA– (%, 95 CI) (0.6, 0.1-1.2) (0.2, 0.3-0.8)
p value for prevalence of PrCa: BRCA+vs BRCA– 0.10 0.4
Follow-up time (yr), median (IQR)
Noncancers 3.0 (2.18, 3.12) 3.0 (2.91, 3.14) 3.0 (2.17, 3.11) 3.0 (2.09, 3.12) 3.0 (2.12, 3.10)
Cancers 0.3 (0.12, 2.05) 0.4 (0.18, 2.27) 1.0 (0.12, 2.28) 0.2(0.10, 1.12) 0.2 (0.06, 1.43)
Total follow-up time, person yrs
Noncancers 7185 2371 1227 2206 1674
Cancers 110 57 20 19 14
Cancer incidence rate (per 1000 person yrs) 15 19 12 14 11
Incidence rate ratio (crude), (95 CI) 1.61 (0.90-2.88) 1.24 (0.70-2.19)
IRR, adjusted for age, ethnicity, country (95 CI) (p value) 1.95 (1.06-3.56) (0.031) 1.36 (0.75-2.45) (0.3)
ASAP= atypical small acinar proliferation; CI = conﬁdence interval; Diff. = difference; HG PIN=high-grade prostate intraepithelial neoplasia; IQR= interquartile
range; IRR= incidence rate ratio; PPV =positive predictive value; PrCa =prostate cancer; PSA=prostate-speciﬁc antigen.
a A total of 95 individuals contribute to both BRCA1 and BRCA2 controls; therefore, the sum of mutation status will not match the total cohort.
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variables, symptoms, or previous screening between groups.
3.2. PrCa detection rates after 3 yr of screening and PPV of
biopsy
At baseline, 2932 participants had a PSA test, 228 (7.7%) had
PSA>3.0 ng/ml, and 69 (2.4%) had cancers diagnosed from
195 biopsies.Cumulatively, after four PSA screens, 527 individuals
(18%) had PSA>3.0 ng/ml and 112 cancers diagnosed from
357 biopsies. In the BRCA2 cohort, 47 (5.2%) cancers were
diagnosed in carriers and 15 (3.0%) in noncarriers;
31 cancers (3.4%) were diagnosed in BRCA1 carriers
compared with 19 (2.7%) in noncarriers (Table 1 and Fig. 2).
Overall PrCa detection rate was 3.8% (112/2932), and the
cancer incidence rate per 1000 person years was 15. The
cancer incidence rates were 19 and 12 in BRCA2 carriers and
[(Fig._2)TD$FIG]
Fig. 2 – A consort diagram of the IMPACT study after four screening rounds. ASAP=atypical small acinar proliferation; PIN=prostate intraepithelial
neoplasia; PPV=positive predictive value; PSA=prostate-specific-antigen.
aControls were men who had a negative predictive genetic test for the BRCA mutation in their family.
bBiopsy—abnormal refers to high-grade PIN and ASAP.
EU RO P E AN U RO L OGY 76 ( 2 019 ) 8 31 – 8 4 2 837noncarriers, respectively (incidence rate ratio [IRR] = 1.95,
p = 0.031), and 14 and 11 in BRCA1 carriers and noncarriers,
respectively (IRR =1.36, p = 0.3).
Overall, PPV of PB was 31%, with 39% and 28% in BRCA2
carriers and noncarriers, respectively (p= 0.17), and 32% and
20% inBRCA1 carriers andnoncarriers, respectively (p= 0.065).
The overall PPV of PSA>3.0 ng/ml was 21%, with 31% and
18% in BRCA2 carriers and noncarriers, respectively (p =
0.025), and 23% and 15% in BRCA1 carriers and noncarriers,
respectively (p = 0.13).
To compare results with the population-based Göteborg
cohort [30], we restricted the IMPACTcohort to entry ages 50–
64yr (SupplementaryTable3). TheGöteborg study report2.5%
PrCa incidence (confidence interval [CI]: 2.2%, 2.8%) after 4yr
[30,31] compared with 5.3% (CI: 4.2–6.5) in IMPACT.
PPV for PB is 30% in the Göteborg cohort and is 26% for
PSA (above threshold). PPV for PB is 33% in IMPACT,
restricted to the Göteborg age range, and 24% for PSA>3.0
ng/ml. When comparing PPVs in the Göteborg cohort with
IMPACT for clinically significant disease, we see a higher
incidence in the BRCA2 carriers for both PSA (p 0.001) and
PB (p 0.001).
As a sensitivityanalysis, analyseswere repeatedexcluding
centres in The Netherlands (Supplementary Table 4) that
screened patients biennially. No differences in the distribu-
tions of cancer incidence, incidence rate, or PPV of PB were
observed. To rule out the BRCA2 control group being anoutlier, the analyses were repeated combining the control
groups, and all significant differences remained.
Analyses were repeated removing cancers diagnosed
within<12moof studyentry (SupplementaryTable5). These
analyses show increased PrCa incidence in BRCA2 carriers;
however, these analyses are currently underpowered.
During the first four screening rounds, the biopsy
compliance rate for raised PSA (>3) was 73% in BRCA2
carriers, 60% inBRCA2noncarriers, 67% inBRCA1 carriers, and
71% in BRCA1 noncarriers. From the 357 biopsies performed
including repeat biopsies, themedian age at biopsy of BRCA2
carrierswas 60yr, comparedwith 64yr in BRCA2noncarriers
(p  0.001). No differences were observed in the BRCA1
cohort (Table 2). When comparing by genetic status, no
differenceswere seen inmedianPSA,which triggeredbiopsy,
time (indays)betweenPSA test andbiopsy, age atbiopsy, and
number of diagnostic cores taken at biopsy.
3.3. Cancer characteristics
Table 3 and Supplementary Table 6 show the characteristics
of all screen-detected PrCa cases diagnosed in patients with
a PSA level of >3.0 ng/ml during the first four screening
rounds.
Themedian age at PrCa diagnosis was 61 yr (interquartile
range [IQR]: 56, 64) in BRCA2 carriers and 64yr (IQR: 60, 66)
in BRCA2 noncarriers (p = 0.044, Kruskal-Wallis). In the
Table 2 – Summary of characteristics of men who underwent biopsies in the first four screening rounds of the IMPACT study.
Total BRCA1+ BRCA1– p value BRCA2+ BRCA2– p value
Total biopsies (n) 357a 98 95 122 54
Biopsy compliance (%) 68 71 75 81 64
Median PSA (ng/ml) to trigger biopsy (IQR) 4.2 (3.5–5.6) 4.2 (3.7–5.6) 4.0 (3.5–4.8) 0.1 4.5 (3.5–5.9) 4.2 (3.4–6.2) 0.8
Median age (yr) at biopsy (IQR) 61 (56–65) 61 (56–64) 61 (56–65) 0.9 60 (56–64) 64 (60–67) <0.001
Median time difference (d) PSA to biopsy (IQR) 51 (27–89) 56 (28–72) 42 (22–79) 0.3 57 (28–94) 50 (25–87) 0.1
Median cores taken, n (IQR) 10 (8–12) 10 (9–12) 10 (8–12) 0.5 10 (8–12) 10 (8–12) 1
IQR= interquartile range; PSA=prostate-speciﬁc antigen.
a Twelve biopsies contribute to both BRCA1 and BRCA2 controls, therefore the sum of mutation status will not match total cohort.
Table 3 – Summary of cancer characteristics of PSA detected cancers using final clinical pathology (ie, if available after prostatectomy)a.
Genetic status BRCA2+ (n =48) BRCA2– (n = 15) p value BRCA1+ (n = 33) BRCA1– (n = 20) p value
Median age (yr) at diagnosis 61 (56, 64) 64 (60, 66) 0.044 62 (57, 66) 61 (58, 62) 0.3
Median PSA (ng/ml) at diagnosis (IQR) 4.5 (3.6, 5.5) 4.2 (3.4, 6.1) 0.9 4.4(3.8, 5.9) 4.4 (3.6, 5.3) 0.7
Gleason score 6 18 (38) 11 (73) 0.019b 18 (55) 13 (65) 0.6a
Gleason score 7 (3 + 4) 15 (31) 1 (7) 9 (27) 4 (20)
Gleason score 7 (4 + 3) 9 (19) 2 (13) 4 (12) 3 (15)
Gleason score 8+ 6 (12) 1 (7) 2 (6) 0
T stage—T1/T2a 16 (35) 8 (57) 0.2b 9 (31) 8 (40) 0.6a
T Stage—T2b 2 (4) 2 (14) 0 1 (5)
T Stage—T2c/T3 28 (61) 4 (29) 20 (69) 11 (55)
Risk categoryc—low 11 (23) 9 (60) 0.011b 10 (30) 4 (20) 0.5a
Risk categoryc—intermediate 7 (14.5) 1 (7) 3 (9) 6 (30)
Risk categoryc—high 30 (62.5) 5 (33) 20 (61) 10 (50)
Screening round diagnosed—1 25 (52) 7 (47) 23 (70) 13 (65)
Screening round diagnosed—2 7 (14.5) 1 (7) 3 (9) 3 (15)
Screening round diagnosed—3 9 (19) 5 (33) 6 (18) 2 (10)
Screening round diagnosed—4 7 (14.5) 2 (13) 1 (3) 2 (10)
Active surveillance 8 (17) 7 (47) 5 (17) 6 (30)
Radical prostatectomy 32 (70) 6 (40) 22 (76) 12 (60)
Nonsurgical treatment 6 (13) 2 (13) 2 (7) 2 (10)
IQR= interquartile range; NICE =National Institute for Health and Care Excellence; PSA=prostate-speciﬁc antigen.
Some pathology information is not available from sites yet.
Values are presented as median (IQR) and n (%).
a Note four cancers included in this analysis were diagnosed as a result of additional off-protocol repeat biopsies in men with high PSA.
b p values calculated on difference between clinically significant disease and non–clinically significant disease.
c Risk category classification system using NICE guidelines [21].
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diagnosis (p = 0.33).
Looking at the overall risk category, 37/48 (77%) BRCA2
carriers had intermediate- or high-risk PrCa (clinically
significant disease), compared with six/15 (40%) BRCA2
noncarriers (p = 0.011, Fisher’s exact). There were no
statistically significant differences between BRCA1 carriers
(70%) and noncarriers (80%; Fig. 3).
Limiting to incident cases,48cancerswerediagnosed:23 in
BRCA2 carriers, eight in BRCA2 noncarriers, 10 in BRCA1
carriers, andseven inBRCA1noncarriers; there isnosignificant
difference by carrier status. No significant difference was also
seenwhen limiting to incident cases and excluding menwho
had had a previous benign biopsy (n=9).
After four screening rounds, no deaths from PrCa were
reported in the IMPACT study participants.
4. Discussion
The IMPACT study is the only international prospective PrCa
screening study conducted exclusively in families withBRCA1/2 mutations. IMPACT will screen all but the Dutch
patients for a total of five screening rounds, and collect
cancer incidence and mortality data for a further 5 yr.
Controversy about PSA level that used to trigger PB
continues, and we have demonstrated that using a PSA level
of >3.0 ng/ml, after four screening rounds, 13% of the total
cohort was recommended to have a PB with a 3.8% cancer
detection rate. The IMPACT study continues to collect
screening data, and a further component of the protocol is to
offer men the option of undergoing PB after the completion
of five screening rounds, irrespective of the PSA level. This
will provide the opportunity to evaluate the number of
clinically significant cancers missed in carriers and non-
carriers when using a PSA threshold of 3.0 ng/ml.
We have demonstrated that the trends reported after the
baseline screen are strengthened after 3 yr of follow-up. The
PPV of PSA>3.0 ng/ml was significantly higher in
BRCA2 mutation carriers (31%) compared with noncarriers
(18%; p = 0.025).When comparedwith the Göteborg cohort,
the PPV of PB in BRCA2 carriers was 41% comparedwith 30%,
therefore biopsying fewer men unnecessarily. As previously
[(Fig._3)TD$FIG]
Fig. 3 – (A) Pie charts showing the overall prostate cancer risk category (as defined by the NICE guidelines—www.nice.org.uk: low: PSA<10 and
Gleason 6 and T1/T2a; intermediate: PSA 10–20 or Gleason 7 or T2b; and high: PSA>20 or Gleason 8–10 orT2c), for all study PSA-detected cancers
in screening rounds 1–4 and broken down by genetic status. (B) Pie charts showing the overall Gleason score, for all study PSA-detected cancers in
screening rounds 1–4 and broken down by genetic status.
NICE=National Institute for Health and Care Excellence; PSA=prostate-specific-antigen.
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BRCA1 carriers and noncarriers [19].
After four screening rounds, BRCA2 carriers have a
statistically significantly higher cancer incidence rate (19)
per 1000 person years compared with noncarriers (12; p =
0.03). With a higher number of cancers detected than
reported previously [22], we have confirmed that
BRCA2 carriers are diagnosed at a younger age (p = 0.044)
than BRCA2 noncarriers and that a significantly greater
proportion of cancers were intermediate- or high-risk
disease (p = 0.011). Overall, 77% of cancers diagnosed in
BRCA2 carriers were clinically significant, compared with
49% in the general population [11]. The youngest age of
diagnosis of clinically significant disease was 41 yr for
BRCA2 carriers and 43yr for BRCA1 carriers, which may
suggest screening from an early age. Regarding the number
of men needed to screen to detect one clinically significant
PrCa after four screening rounds, screening 60 BRCA2
carriers aged 40–54yr and 13 carriers aged 55–69 yr will
detect one clinically significant PrCa, respectively. Eventu-
ally, long-term follow-up data on the clinical benefit of early
detection are needed to determine the best starting age.
Analyses of the cancer detection rates, PPV, and
characteristics were repeated excluding prevalent cancers
(PrCa diagnosed within 12mo of baseline PSA). It was found
that whilst not statistically significant, there was greater
PrCa incidence in BRCA2 carriers than in noncarriers (9.1 vs
6.4), and substantially higher numbers of intermediate- andhigh-risk cancers were detected in BRCA2 carriers than in
noncarriers (p = 0.074). Owing to the relatively small
number of cancers diagnosed in the BRCA2 noncarriers,
we also re-ran these analyses combining the two noncarrier
control groups, and statistically significant differences in
tumour characteristics remained. In addition, clinically
significant cancers were diagnosed at every screening
round, supporting the use of systematic PSA screening.
After 3 yr of follow-up, it is possible that disease was
present, but not detectable by PSA, at study entry. A further
aim of the IMPACT study is to offer PB to all men after five
screening rounds, to evaluate the utility of a baseline biopsy
irrespective of the PSA level with respect to cancer
prevalence and tumour characteristics. However, it is
reassuring to see from the data presented that using a
cut-off of 3 ng/ml, the majority of the tumours detected
were at an early stage.
No statistically significant differences were detected in
age of onset or cancer characteristics between BRCA1
carriers and noncarriers. Further follow-up is required to
conclude the clinical management of BRCA1 carriers.
Similar to our report for the IMPACT baseline screen [22],
the ProtecT score using the 4K panel (Supplementary
material) was able to predict PB outcome, with a
discrimination of 0.73 for high-grade disease. This adds
further evidence to support the use of additional biological
markers, such as the 4K panel in improving the detection of
clinically significant PrCa.
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A limitation of IMPACT is that not all men comply with the
studyprotocol, and therefore cancersmaybemissedeither in
menwho refuse PB, or inmenwho are advised locally to have
MRI or repeat PSA instead of a PB. Genetic status may play a
role in protocol compliance with fewer noncarriers, particu-
larly BRCA2 noncarriers, proceeding with a PB (73% vs 60%).
This differential biopsy rate is likely to have underestimated
the PrCa incidence in both BRCA2 carriers and noncarriers.
Complete datawould be expected to strengthen the power to
detect the difference in clinically significant disease between
these groups. As follow-up will continue for a further 5 yr,
these data will become available as part of future analyses.
The higher observed biopsy rate within BRCA2 carriers could
represent variation in how health professionals counselmen
with high PSA levels, with a bias towards encouraging biopsy
in BRCA2 carriers. Of note, no variationwas seen between the
number of cores taken at biopsy and mutation status.
Variation was observed between sites and across the course
of the study as the protocol increased from 10 to 12 biopsy
cores as standard practice changed.
Given the rarity of BRCA1/2mutations, it was not possible
to restrict the protocol to those with no prior urinary
symptoms or PSA testing. Those with a prior PB were
excluded. There was no difference in cancer incidence rates
in those with symptoms or prior PSA testing.
In comparingwith the Göteborg cohort, we acknowledge
that this general population cohort is not stratified for BRCA
status; however, the population frequency of BRCA1/2
mutations is low. This study also used biennial rather than
yearly PSA and was restricted to sextant PB, and therefore
cancer detection rates at PB may be lower than that in
IMPACT.
IMPACT started in 2005, prior to the implementation of
multiparametric MRI in PrCa screening [17,18]. Without a
systematic evaluation of the use of MRI in men at
genetically high risk, it is difficult to extrapolate general
population data to this setting and needs further research.
The Dutch protocol, as outlined above, screened men
every 2 yr, and also included digital rectal examination and
PCA3 in the algorithm of whether to proceed to biopsy or
not. Therefore, some men with PSA<3.0 ng/ml were
biopsied, some of whom were diagnosed with cancer.
However, despite this differing protocol in this cohort,
sensitivity analyses excluding the Dutch data demonstrate
that this approach did not affect the overall results.
A challenge of a longitudinal study such as IMPACT is in
balancing the standardisation of procedures and changes in
practice. For example, there have been changes in PB during
the course of this study; the protocol has been updated to
increase the number of diagnostic cores from10 to12during
the study’s duration. Some centres have used the transper-
ineal approach in line with local practice guidelines.
5. Conclusions
We demonstrate that, after four annual PSA screening
rounds, BRCA2mutation carriers have a higher incidence ofPrCa, are diagnosed at a younger age, and present withmore
clinically significant tumours than BRCA2 noncarriers.
Further follow-up is required to assess the role of screening
in BRCA1 mutation carriers. Therefore, these data support
the use of systematic PSA screening in male BRCA2 carriers.
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